Dong-E-E-Jiao stock: Price History and Returns
000423.SZDong-E-E-Jiao's share price fell by 1.2% a year over the last 10 years, 11.1% in total (in CNY). With dividends reinvested, however, the return was +1.6% a year, +17.6% in total. The dividend yield is 5.33% today.
This shows what Dong-E-E-Jiao Co.,Ltd. has returned on the stock market in the past. Past returns say nothing about the future.
Daily figure as of 20 Nov 2026
Share Price Since 2006
How Dong-E-E-Jiao Has Performed
In its best year, 2007, the share price more than doubled at +232.9%, the weakest was 2008 at −58.5%. The stock has not yet recovered its largest drawdown of 65.7% between June 2017 and March 2020 and trades 28.5% below the high today. Dividends made a big difference: over 10 years they added 2.8 percentage points a year. From 2011 to 2014 the stock fell four years in a row.
About every other calendar year since 2007 ended with a loss, 9 of 19. Since the low in March 2020 the share price has risen more than twofold. The longest run of gains lasted from 2015 to 2017, three years in a row. 2025 was a weak year at −21.7%, well below the 10-year average of −1.2% a year. Since the start of the year the stock is up 6.3%.
How Dong-E-E-Jiao Compares
Over 10 years Dong-E-E-Jiao trailed the MSCI World: with dividends +1.9% a year against +12.5% for the index, in US dollars. Over one year, Dong-E-E-Jiao trailed 56% of the 73 other stocks in the Drug Manufacturers (Specialty & Generic) industry. Over five years the figure was 52%. The highest share price returns over five years in the Drug Manufacturers (Specialty & Generic) industry came from Eton Pharmaceuticals, PharmaEssentia and Regencell Bioscience Holdings.
| Period | Dong-E-E-Jiao | MSCI World |
|---|---|---|
| 1 year | +21.2% | +10.8% |
| 5 years | +7.9% | +9.5% |
| 10 years | +1.9% | +12.5% |
Returns of Industry Peers
Among its industry peers, Gland Pharma led over one year (+86.1%) and Sumitomo Pharma trailed furthest (−22.3%).
| Stock | 1 year | 5 years |
|---|---|---|
| China Resources Sanjiu Medical & Pharmaceutical | −9.7% | +83.4% |
| Supernus | −13% | +65.5% |
| Gland Pharma | +86.1% | −3.7% |
| Sumitomo Pharma | −22.3% | +29.1% |
| Ipca Laboratories | +28.5% | +79.1% |
What Became of $1,000
$1,000 invested in Dong-E-E-Jiao 20 years ago is worth $7,179 today, $10,426 with dividends reinvested.
With dividends means each dividend is reinvested at the closing price on the ex-date, before taxes and costs. The index is represented by an accumulating ETF, dollar amounts at ECB rates. Industry figures are share price returns only, in each exchange's currency, as of 20 Nov 2026.
Returns by Period
| Period | Total | Per year |
|---|---|---|
| 1 year | +7.4% | +7.4% |
| 3 years | +5.4% | +1.8% |
| 5 years | +25.1% | +4.6% |
| 10 years | −11.1% | −1.2% |
| 15 years | +11.5% | +0.7% |
| 20 years | +508.9% | +9.5% |
Returns by Calendar Year
Figures as a table
| Year | Closing price | Return |
|---|---|---|
| 2026 to date | $7.83 | +6.3% |
| 2025 | $7.36 | −21.7% |
| 2024 | $9.41 | +27.2% |
| 2023 | $7.40 | +21.2% |
| 2022 | $6.11 | −16.5% |
| 2021 | $7.31 | +25.9% |
| 2020 | $5.81 | +9.4% |
| 2019 | $5.31 | −10.6% |
| 2018 | $5.93 | −34.4% |
| 2017 | $9.04 | +11.9% |
| 2016 | $8.08 | +3% |
| 2015 | $7.84 | +40.3% |
| 2014 | $5.59 | −5.8% |
| 2013 | $5.93 | −2.1% |
| 2012 | $6.06 | −5.9% |
| 2011 | $6.44 | −15.9% |
| 2010 | $7.67 | +95.4% |
| 2009 | $3.92 | +93.7% |
| 2008 | $2.03 | −58.5% |
| 2007 | $4.88 | +232.9% |
Peak Price and Largest Drawdown
This is the pure share price return in CNY from closing prices, adjusted for stock splits. Dividends come on top and are not included here.
Work out your own amount and period in the What-if calculatorData and Required Disclosures
- ; time horizon around 12 months
- Rated Strong since 7 Nov 2026; valuation signal Fairly valued since 18 Nov 2026
- Price: closing price of 20 Nov 2026
- Amounts in US dollars at the ECB reference rate of 19 Nov 2026 ($1 = CN¥6.6667)
- Data from Financial Modeling Prep (FMP) based on the company's reports, latest fiscal year 2025. MEQIRI calculates the score and fair value itself every night.
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.
